Non-Infectious Macular Edema Treatment Market Set to Experience Exponential Growth by 2031 with Prominent Demand for Corticosteroids in North America and Europe

Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Non-infectious Macular Edema Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)" report has been added to's offering.

The latest comprehensive research publication on the Non-Infectious Macular Edema Treatment Market provides insightful analysis of the dynamic growth trajectory projected for the global industry. This data-rich study encompasses pivotal aspects, ranging from product innovations to regional market prospects, fostering an informed strategic understanding for stakeholders in the ophthalmology sector.

Advancements in Macular Edema Therapies

A sharp rise in the incidence of diabetes-related eye conditions, coupled with heightened awareness and screening protocols, has substantially augmented the demand for non-infectious macular edema treatments. The report underscores key treatment modalities, such as Anti-VEGF agents, which historically spearheaded the market, while indicating a momentous shift towards alternative therapies due to their long-term side effects.

Increased Adoption of Intravitreal Implants and Immunosuppressants

The advent of Intravitreal Implants such as Eylea, Ozurdex, and Iluvien proved instrumental in the accelerated expansion of the industry. Especially in regions like North America and Europe, where these innovative therapies have supplanted traditional laser photocoagulation treatments post their introductions in the market. The ease of administration and potency of low-dose corticosteroid implants are significant factors propelling the widespread acceptance of Intravitreal therapies, which is meticulously detailed in the report.

Immunosuppressant Therapies

As pivotal adjuncts or primary choices in the macular edema treatment regime, immunosuppressant therapies including methotrexate, azathioprine, and mycophenolate mofetil, are attracting medical preference. These agents have been particularly effective, garnering notable interest across the non-infectious macular edema treatment market and are predicted to be major drivers of growth.

  • Comprehensive Segmentation: The report elucidates on numerous market segments, offering a granular look at the drug types, indications, routes of administration, and distribution channels.
  • Regional Insights: While highlighting the global scope, the study pays close attention to region-specific trends, with potent growth markers identified in territories such as North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa.

Despite the rosy predictions, the non-infectious macular edema treatment landscape encounters notable challenges such as the prevalence of counterfeit drugs, high costs associated with treatment regimens, and the introduction of biosimilars impacting the branded drugs market. These critical factors are thoroughly evaluated within the report to equip industry participants with a nuanced understanding of the market challenges.

The comprehensive research compilation emerges as an essential tool for key players, investors, healthcare professionals, and regulatory authorities seeking to navigate the complex contours of the non-infectious macular edema treatment market. With an emphasis on data-driven insights, the publication excels in charting a detailed roadmap for the future of ocular healthcare treatments and market dynamics through the decade leading up to 2031.

As the global ecosystem of healthcare continues to evolve, multifaceted research such as this on the Non-Infectious Macular Edema Treatment Market remains invaluable, assisting stakeholders to align with market exigencies and steer towards sustainable growth.

A selection of companies mentioned in this report includes

  • Allergan, Plc.
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • F. Hoffman - La Roche Ltd.
  • AbbVie Inc.
  • Bayer AG
  • Valeant Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Clearside Biomedical, Inc.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contact Data